This study analyzes the cost of adverse events associated with metastatic renal cell carcinoma (mRCC) treatments of pazopanib and sunitinib. A cost analysis was performed based on the published data of the COMPARZ study. All adverse events (AEs) were identified based on the AEs reported in this study, Cost information related to the the treatment of the most frequent adverse events (>15%) in the study population (n= 1,100 individuals) were obtained. These events included in the analysis were hepatotoxicity, anemia, nausea, fatigue and diarrhea. The perspective adopted in this analysis was of the Unified Health System (SUS) and Brazilian Supplementary Healthcare (SS). For reckoning purposes, the Medication Market Regulation Chamber (CMED/ ANVISA) listed prices were used. Were obtained the following results for suninitib vs pazopanib treatment course respectively: In SUS perspective: Increased ALT (BRL 107,24 / BRL 149,63), Anemia (BRL 47,72 / BRL 24,65), Diarrhea (BRL 231,44 / BRL 255,8), Fatigue (BRL 22,67 / BRL 19,79), Hypertension (BRL 618,79 / BRL 694,26), Nausea (BRL 176,49 / BRL 172,65), Thrombocytopenia (BRL 66,29 vs BRL 34,85). When considering costs incurred from private pay perspective such as SS, we observed the values were Increased ALT (BRL 810,84 / BRL 1131,40), Anemia (BRL 269,31 / BRL 139,14), Diarrhea (BRL 787,41 vs BRL 870,29), Fatigue (BRL 205,51 / BRL 179,42), Hypertension (BRL 1017,91 / BRL 1142,04), Nausea (BRL 782 / BRL 765), Thrombocytopenia (BRL 328,49 / BRL 172,67). A therapy that has less financial impact on the treatment of adverse events is the choice of sunitinib for both public (6% decrease) and private (5%).